CoChat

Treatment with abatacept prevents experimental dermal fibrosis and induces regression of established inflammation-driven fibrosis

The DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.

Abstract

Objective Activated T cells are the main component of the inflammatory skin infiltrates that characterise systemic sclerosis (SSc). Our aim was to investigate the efficacy of abatacept, which tempers T-cell activation, in reducing skin fibrosis in complementary mouse models of SSc. Methods The antifibrotic properties of abatacept were evaluated in the mouse models of bleomycin-induced dermal fibrosis and sclerodermatous chronic graft-versus-host disease, reflecting early and inflammatory stages of SSc. Thereafter, we studied the efficacy of abatacept in tight skin (Tsk-1) mice, an inflammation-independent mouse model of skin fibrosis. Results Abatacept efficiently prevented bleomycin-induced skin fibrosis and was also effective in the treatment of established fibrosis. In this model, abatacept decreased total and activated T-cell, B-cell and monocyte infiltration in the lesional skin. Abatacept did not protect CB17-SCID mice from the development of bleomycin-induced dermal fibrosis, which supports that T cells are necessary to drive the antifibrotic effects of abatacept. Upon bleomycin injections, skin interleukin (IL) 6 and IL-10 levels were significantly reduced upon abatacept treatment. Moreover, treatment with abatacept ameliorated fibrosis in the chronic graft-versus-host disease model, but demonstrated no efficacy in Tsk-1 mice. The tolerance of abatacept was excellent in the three mouse models. Conclusions Using complementary models, we demonstrate that inhibition of T…

Overview

Integrity signals

Registry

Crossref · 10.1136/annrheumdis-2015-208213

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

1 retracted

Show all 41 references

Cited by

See all 72

Metadata

Authors
Ponsoye, M., Frantz, C., Ruzehaji, N., Nicco, C., Elhai, M., Ruiz, B., Cauvet, A., Pezet, S., Brandely, M. L., Batteux, F., Allanore, Y., & Avouac, J.
Affiliations
  • Centre National de la Recherche Scientifique (FR)
  • Hôpital Cochin (FR)
Corresponding author
Avouac, Jérôme
Venue
Annals of the Rheumatic Diseases
Publisher
Elsevier BV
Published
2016-12
Volume
75
Issue
12
Pages
2142-2149
ISSN
0003-4967 (ISSN-L)
OpenAlex
W2345318809
Cited by
70
References
42
Citations by year
2026: 1 · 2025: 5 · 2024: 1 · 2023: 9 · 2022: 9 · 2021: 10 · 2020: 13 · 2019: 6 · 2018: 8 · 2017: 5 · 2016: 3
FWCI
6.67
Type
journal article
Language
en
Open access
closed
Locations
  • Annals of the Rheumatic Diseases (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
  • Health Sciences › Medicine › Rheumatology › Dupuytren's Contracture and Treatments
  • Health Sciences › Medicine › Dermatology › Dermatologic Treatments and Research
Keywords
abatacept, systemic sclerosis, skin fibrosis, T cell activation, bleomycin-induced fibrosis, sclerodermatous chronic graft-versus-host disease, skin inflammation, interleukin-6, IL-10, antifibrotic therapy, fibrosis regression
MeSH terms
Abatacept, Animals, B-Lymphocytes, Bleomycin, Disease Models, Animal, Fibrosis, Graft vs Host Disease, Lymphocyte Activation, Scleroderma, Systemic, Skin Diseases, T-Lymphocytes, Interleukin-6, Interleukin-10, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Treatment with abatacept prevents experimental dermal fibrosis and induces regression of established inflammation-driven fibrosis. https://app.cochat.ai/papers/10.1136/annrheumdis-2015-208213
The paper
Ponsoye, M., Frantz, C., Ruzehaji, N., Nicco, C., Elhai, M., Ruiz, B., Cauvet, A., Pezet, S., Brandely, M. L., Batteux, F., Allanore, Y., & Avouac, J. (2016). Treatment with abatacept prevents experimental dermal fibrosis and induces regression of established inflammation-driven fibrosis. Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2015-208213

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.